Search PubMed⌕ Search

Biomedical subjects

H Ujike

Publications and source records attributed to H Ujike.

86 records · Page 5Linked to original sources
PubMed1989

[Korsakoff's syndrome as a prominent feature of bilateral paramedian thalamic infarction--a case report].

We reported the first Japanese case of bilateral paramedian thalamic infarction associated with prominent Korsakoff's syndrome. 53-year-old man suffered from semicoma on the morning of September 16th, 1988. After recovery of consciousness disturbance, neurological examination revealed vertical eye gaze palsy, areflexia of lower extremities, apathy with hypersomnia and amnesia. Amnesia was accompanied with prominent confabulation, disorientation and lack of insight into his own disability. While X ray-CT revealed only ambiguous low density area in the bilateral thalamus, MRI of horizontal section by short spin echo revealed symmetrical low signal area restricted in the paramedian area of bilateral thalamus, and that of coronal section revealed characteristic butterfly-shaped lesion. Left BAG revealed that both posterior thalamoperforating arteries showed type 3 variation of Percheron's classification which arisen from artery arcade bridging between both side of interpeduncular segment of posterior cerebral artery. He showed gradual improvement in apathy with hypersomnia and disorientation but not in Korsakoff's syndrome nor ophthalmoplegia.

Alcohol Amnestic Disorder↗
PubMed1989

[Two siblings of juvenile Parkinson's disease dystonic type (Yokochi type 3) and hereditary progressive dystonia with marked diurnal fluctuation (Segawa)].

Two siblings of juvenile parkinson's disease dystonic type (JPA Yokochi type 3) and hereditary progressive dystonia with marked diurnal fluctuation (Segawa, HPD) were reported. The family had consanguinity. The elder brother suffered from resting tremor of legs, left foot dystonia and left pes equinovarus at the age of 12 years and 5 months. At the age of 15, he developed tremor and rigidity of upper extremities. These symptoms did not show diurnal fluctuation and markedly responded to L-dopa treatment. He implicated wearing-off phenomenon at the age of 16, and on-off phenomenon and L-dopa-induced dyskinesia at the age of 18. He was diagnosed as JPA Yokochi type 3. The younger brother suffered from left pes equinovarus, right scoliosis and foot dystonia at the age of 8 years. These symptoms showed remarkable diurnal fluctuation, which ameliorated after sleep or rest and worsened afternoon. He noticed fine postural tremor of upper extremities at psychological tense state and right pes varus at the age of 16. He received L-dopa at the age of 17 and became to be remission. He was diagnosed as HPD. Since these two disorders related to basal ganglia show similar clinical symptoms mainly consisting of foot dystonia and similar clinicopharmacological response to L-dopa, it has been assumed that shared abnormalities in pathomechanism can exist between them. This study indicates that the same gene-regulated abnormality may participate in the development of these two disorders.

Child↗
PubMed1988

Effects of acute and long-term treatment with methamphetamine on substance P concentration and receptor numbers in the rat brain.

To examine biochemical changes in brain substance P (SP) systems associated with development of behavioral sensitization induced by methamphetamine (MAP), regional substance P-like immunoreactivity (SP-LI) and SP receptor binding in the rat brain were measured after acute and long-term MAP administration. Single administration of 8 mg/kg MAP significantly reduced the striatal SP-LI concentration 1 h after the injection. This reduction was blocked by pretreatment with haloperidol. Although repeated administration of 4 mg/kg MAP for 14 consecutive days did not affect the SP-LI concentration in any brain regions including the striatum, it decreased specific SP receptor binding in the striatum and increased those in the frontal cortex. Scatchard analysis of saturation isotherm of specific SP binding revealed that the decreased specific SP binding in the striatum resulted from a decrease in the maximal number (Bmax) of SP receptors and that increased binding in the frontal cortex resulted from an increase in Bmax. These changes in SP receptor binding lasted for at least 7 days. It is emphasized that the persisting changes induced by long-term MAP administration in the SP receptor may contribute to behavioral sensitization to MAP in rats and may be associated with neuronal mechanisms in MAP psychosis.

Animals↗
PubMed1988

Effect of L-threo-3,4-dihydroxyphenylserine on regional cerebral blood flow in patients with Parkinson's disease.

Regional cerebral blood flow (rCBF) was measured by the 133Xe inhalation technique in 9 patients with Parkinson's disease and in 1 patient with pure akinesia before and during treatment with L-threo-3,4-dihydroxyphenylserine (DOPS). L-DOPS alone was administered in 4 patients, and combined with L-DOPA or bromocriptine in 6 patients. The mean, hemispheric and regional CBF was unaffected by the chronic administration of L-DOPS. In addition, no significant difference in the mean CBF was observed between the patients who showed marked or moderate improvement in parkinsonian symptoms during the treatment with L-DOPS and those who showed slight improvement or no change, or between the group treated with L-DOPS alone and the group treated in combination with L-DOPS and other drugs. These results indicate that L-DOPS does not increase the CBF in parkinsonian patients, thus the anti-parkinsonian effects of the agent are not mediated by changes in CBF.

Adult↗
PubMed1987

Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes with recurrent abdominal symptoms and coenzyme Q10 administration.

A male with mitochondrial myopathy, encephalopathy, lactic acidemia, and strokelike episodes is reported. He had also recurrent episodes of ileus. Muscle biopsy revealed ragged-red fibres. The cytochemistry of cytochrome c oxidase (CCO) showed scattered nonstained fibres, while all muscle fibres were heavily stained by immunocytochemistry using CCO antibody. These findings suggest that partical CCO deficiency may be present in the skeletal muscles of the patient. NADH cytochrome c reductase in the patient's muscle mitochondria was low compared with normal controls (about 26%), although succinate cytochrome c reductase was normal. Coenzyme Q10 administration (90 mg/day) did not improve CSF lactate levels, but did decrease plasma lactate levels. His muscle weakness slightly improved.

Acidosis, Lactic↗
PubMed1986

Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.

L-Threo-3,4-dihydroxyphenylserine (L-threo-DOPS) was administered as a means of treating akinesia in 9 patients with Parkinson's disease and one with pure akinesia. Akinetic symptoms were improved in 7 of 10 patients. During chronic L-threo-DOPS treatment, cerebrospinal fluid (CSF) and plasma concentrations of free 3-methoxy-4-hydroxyphenylglycol (MHPG) and L-threo-DOPS were measured in these 10 patients. The results show that there were no significant changes in either CSF or plasma free MHPG concentrations before or during L-threo-DOPS administration. The L-threo-DOPS concentration during treatment was not measurable in the CSF of 2 patients nor in the plasma of 1 out of 4 patients given only L-threo-DOPS. It was, however, measured in all patients treated with a combination of L-threo-DOPS and L-DOPA plus carbidopa. The results show that L-threo-DOPS is transported into the CSF, and suggest that its active mechanism may be further clarified by studying its action on not only noradrenaline, but also other neurotransmitters.

Adult↗
PubMed1985

Effective treatment of pure akinesia with L-threo-3,4-dihydroxyphenylserine (DOPS): report of a case, with pharmacological considerations.

A patient with pure akinesia, who experienced freezing only when starting to walk backward or when turning, is reported. L-DOPA, maprotiline, clonazepam, DL-threo-3,4-dihydroxyphenylserine (DOPS), and L-threo-DOPS were administered to the patient. Only DL-threo-DOPS and L-threo-DOPS were effective, but they concurrently brought on a hypomanic state. Combining carbidopa with DL (or L)-threo-DOPS did not change the effectiveness of the treatment. DL (or L)-threo-DOPS did not affect monoamine metabolites in the cerebrospinal fluid (CSF). The effectiveness of L-threo-DOPS on freezing, the induction of affective changes, and the absence of 3-methoxy-4-hydroxyphenylglycol alteration in the CSF suggest that L-threo-DOPS acts centrally but may not directly involve the noradrenergic system.

Droxidopa↗
PubMedDate not supplied

Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms.

Several studies indicate that the mu-opioid receptor plays a role in addiction not only to opiate drugs but also to alcohol and non-opiate addictive drugs. Our studies aim to reveal the associations between gene polymorphisms and methamphetamine (MAP) dependence/psychosis. We newly identified several polymorphisms and four substantial linkage disequilibrium (LD) blocks in the mu-opioid receptor (OPRM1) gene. We found significant differences in both genotype and allele frequencies of the single-nucleotide polymorphism (SNP) IVS2+G691C between control (n=232) and MAP-dependent/psychotic patients (n=128). There was also a significant association between IVS2+G691C and patients with transient psychosis. These results suggest that the OPRM1 gene variations may be a factor in development and prognosis of MAP psychosis.

Adult↗